RAIN vs. LIAN, WENA, PHXM, KLDO, NMTR, PTEIQ, ATNFW, SXTPW, DRTSW, and WENAW
Should you be buying Rain Oncology stock or one of its competitors? The main competitors of Rain Oncology include LianBio (LIAN), ANEW Medical (WENA), PHAXIAM Therapeutics (PHXM), Kaleido Biosciences (KLDO), 9 Meters Biopharma (NMTR), PolarityTE (PTEIQ), 180 Life Sciences (ATNFW), 60 Degrees Pharmaceuticals (SXTPW), Alpha Tau Medical (DRTSW), and Anew Medical (WENAW). These companies are all part of the "biotechnology" industry.
Rain Oncology vs.
Rain Oncology (NASDAQ:RAIN) and LianBio (NASDAQ:LIAN) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, risk, community ranking, media sentiment, valuation, institutional ownership, profitability, analyst recommendations and dividends.
Rain Oncology has a beta of 0.27, meaning that its share price is 73% less volatile than the S&P 500. Comparatively, LianBio has a beta of 0.23, meaning that its share price is 77% less volatile than the S&P 500.
Rain Oncology is trading at a lower price-to-earnings ratio than LianBio, indicating that it is currently the more affordable of the two stocks.
LianBio's return on equity of -33.17% beat Rain Oncology's return on equity.
Rain Oncology received 22 more outperform votes than LianBio when rated by MarketBeat users. Likewise, 52.00% of users gave Rain Oncology an outperform vote while only 36.36% of users gave LianBio an outperform vote.
65.8% of Rain Oncology shares are owned by institutional investors. Comparatively, 74.8% of LianBio shares are owned by institutional investors. 17.4% of Rain Oncology shares are owned by insiders. Comparatively, 7.6% of LianBio shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
In the previous week, LianBio had 1 more articles in the media than Rain Oncology. MarketBeat recorded 1 mentions for LianBio and 0 mentions for Rain Oncology. LianBio's average media sentiment score of 0.00 beat Rain Oncology's score of -0.29 indicating that LianBio is being referred to more favorably in the news media.
Summary
LianBio beats Rain Oncology on 7 of the 12 factors compared between the two stocks.
Get Rain Oncology News Delivered to You Automatically
Sign up to receive the latest news and ratings for RAIN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Rain Oncology Competitors List
Related Companies and Tools
This page (NASDAQ:RAIN) was last updated on 1/15/2025 by MarketBeat.com Staff
Free RAIN Stock Alerts